Valeant Pharmaceuticals Intl Inc.: What Michael Pearson’s Testimony Means for the Company

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares declined by more than 7% after Michael Pearson was subpoenaed by a Senate committee.

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares plunged by 7% on Monday after a Senate committee subpoenaed outgoing CEO Michael Pearson.

So what exactly is in store for Mr. Pearson, and why did investors react so negatively?

What Mr. Pearson can expect

Valeant is fighting a multifront battle nowadays. The company is facing questions regarding its financial health, its business model, Philidor, investigations from regulators, corporate governance, and its financial reporting. But Congress only cares about one thing: Valeant’s history of steep drug-price increases.

In a sense, this is good news for Mr. Pearson. He won’t have to answer any questions that he is not ready to answer. But here’s the bad news: politicians are furious with Valeant’s drug-pricing practices, especially regarding Isuprel and Nitropress, two heart medications the company acquired in 2015. Valeant raised these drugs’ prices by 525% and 212%, respectively.

And the politicians aren’t alone. Polls have shown the American public is fed up with the rising cost of drugs. Republican voters want action on this issue just as much as they want Obamacare repealed. Even PhRMA, the chief pharmaceutical lobby, isn’t standing by Valeant; instead, it’s comparing the company to the much-maligned Turing Pharmaceuticals.

So Mr. Pearson can expect some harsh treatment at the hearing, which takes place on April 27.

Why the shares reacted negatively

We all know how Washington works. Politicians love to grandstand in front of TV cameras, but when it comes to passing meaningful policies, they are much more hesitant. So there’s reason to believe Mr. Pearson’s testimony won’t be meaningful in the long run.

But there are legitimate reasons to be worried. First of all, Mr. Pearson is not known to be a strong public speaker.

Secondly, research has shown that when drug prices are under public scrutiny, drug-price increases tend to slow dramatically. So the longer that Valeant is made out to be the villain, the more impact it will have on its business model.

And to top it all off, Valeant’s financial condition is so poor that short-term factors matter that much more. Put another way, by the time the dust settles on this issue, Valeant could even be bankrupt. This is something you need to think about before buying the stock.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned.  Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Nuclear power station cooling tower
Energy Stocks

Why Shares of Cameco Are Powering Higher

Cameco (TSX:CCO) shares have surged more than 400% in the last five years alone, with more growth on the way.

Read more »

A bull outlined against a field
Stocks for Beginners

Bull Market Buys: 2 TSX Stocks to Own for the Long Run

Are you looking for stocks that could see a bull run for decades ahead? Here are two top TSX stocks…

Read more »

financial freedom sign
Dividend Stocks

Million-Dollar TFSA: 1 Way to Achieve to 7-Figure Wealth

Achieving seven-figure TFSA wealth is doable with two large-cap, high-yield dividend stocks.

Read more »

analyze data
Dividend Stocks

How Much Will Manulife Financial Pay in Dividends This Year?

Manulife stock's dividend should be safe and the stock appears to be fairly valued.

Read more »

food restaurants
Dividend Stocks

Better Stock to Buy Now: Tim Hortons or Starbucks?

Starbucks and Restaurant Brands International are two blue-chip dividend stocks that trade at a discount to consensus price targets.

Read more »

Diggers and trucks in a coal mine
Metals and Mining Stocks

1 Canadian Mining Stock Worth a Long-Term Investment

Cameco (TSX:CCO) stock could be a great long-term investment for Canadian growth seekers.

Read more »

Pot stocks are a riskier investment
Investing

Could Investing $10,000 in Aurora Cannabis Stock Make You a Millionaire?

Let's dive into whether Aurora Cannabis (TSX:ACB) could be a potential millionaire-maker stock, or a dud, over the long term.

Read more »

stock analysis
Energy Stocks

Is Enbridge Stock a Good Buy in May 2024?

Boasting high-yielding dividends and a stable underlying business, Enbridge (TSX:ENB) might be a great buy for your self-directed investment portfolio…

Read more »